108 related articles for article (PubMed ID: 15292299)
21. Gastric undifferentiated carcinoma with diffuse c-kit overexpression and focal neuroendocrine differentiation.
Mori D; Akashi M; Baba K; Morito K; Shibaki M; Hashimoto M; Nakamura A; Mawatari S; Sato S
Pathol Res Pract; 2013 Feb; 209(2):132-4. PubMed ID: 23347914
[TBL] [Abstract][Full Text] [Related]
22. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors.
Volante M; Allìa E; Gugliotta P; Funaro A; Broglio F; Deghenghi R; Muccioli G; Ghigo E; Papotti M
J Clin Endocrinol Metab; 2002 Mar; 87(3):1300-8. PubMed ID: 11889202
[TBL] [Abstract][Full Text] [Related]
23. Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors.
Arnaldi G; Mancini T; Kola B; Appolloni G; Freddi S; Concettoni C; Bearzi I; Masini A; Boscaro M; Mantero F
J Clin Endocrinol Metab; 2003 Dec; 88(12):5834-40. PubMed ID: 14671177
[TBL] [Abstract][Full Text] [Related]
24. [A case of primary neuroendocrine carcinoma of liver presenting with liver abscess].
Lee SH; Kim KA; Lee JS; Oh DH; Bae WK; Kim NH; Moon YS; Kim HS
Korean J Gastroenterol; 2006 Oct; 48(4):277-80. PubMed ID: 17060722
[TBL] [Abstract][Full Text] [Related]
25. Increased density of ghrelin-expressing cells in the gastric fundus and body in Prader-Willi syndrome.
Choe YH; Song SY; Paik KH; Oh YJ; Chu SH; Yeo SH; Kwon EK; Kim EM; Rha MY; Jin DK
J Clin Endocrinol Metab; 2005 Sep; 90(9):5441-5. PubMed ID: 15956087
[TBL] [Abstract][Full Text] [Related]
26. Endogenous circulating ghrelin does not mediate growth hormone rhythmicity or response to fasting.
Avram AM; Jaffe CA; Symons KV; Barkan AL
J Clin Endocrinol Metab; 2005 May; 90(5):2982-7. PubMed ID: 15713719
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of ghrelin concentration of plasma and tumor tissue in patients with gastric cancer.
An JY; Choi MG; Noh JH; Sohn TS; Jin DK; Kim S
J Surg Res; 2007 Dec; 143(2):344-9. PubMed ID: 17688884
[TBL] [Abstract][Full Text] [Related]
28. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions.
Cremonini F; Camilleri M; Vazquez Roque M; McKinzie S; Burton D; Baxter K; Zinsmeister AR
Gastroenterology; 2006 Nov; 131(5):1431-9. PubMed ID: 17101319
[TBL] [Abstract][Full Text] [Related]
29. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
[TBL] [Abstract][Full Text] [Related]
30. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of neuroendocrine components in gastric carcinomas.
Park JY; Ryu MH; Park YS; Park HJ; Ryoo BY; Kim MG; Yook JH; Kim BS; Kang YK
Eur J Cancer; 2014 Nov; 50(16):2802-9. PubMed ID: 25201164
[TBL] [Abstract][Full Text] [Related]
32. Dose-dependent response of plasma ghrelin and growth hormone concentrations to bovine ghrelin in Holstein heifers.
ThidarMyint H; Yoshida H; Ito T; Kuwayama H
J Endocrinol; 2006 Jun; 189(3):655-64. PubMed ID: 16731795
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine gastric carcinoma expressing somatostatin: a highly malignant, rare tumor.
Waisberg J; de Matos LL; do Amaral Antonio Mader AM; Pezzolo S; Eher EM; Capelozzi VL; Speranzini MB
World J Gastroenterol; 2006 Jun; 12(24):3944-7. PubMed ID: 16804989
[TBL] [Abstract][Full Text] [Related]
35. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
36. Histological and immunohistochemical study of composite neuroendocrine-exocrine carcinomas of the stomach.
Rayhan N; Sano T; Qian ZR; Obari AK; Hirokawa M
J Med Invest; 2005 Aug; 52(3-4):191-202. PubMed ID: 16167538
[TBL] [Abstract][Full Text] [Related]
37. [Gastric neuroendocrine carcinoma and gastric carcinoma with neuroendocrine cell differentiation: a clinical and prognostic analysis].
Wang HF; Wu AW; Yuan P; Liu YQ; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Feb; 14(2):96-9. PubMed ID: 21365498
[TBL] [Abstract][Full Text] [Related]
38. [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide].
Rischke HC; Staib-Sebler E; Mose S; Adams SW; Herrmann G; Böttcher HD; Lorenz M
Dtsch Med Wochenschr; 1999 Feb; 124(7):182-6. PubMed ID: 10093577
[TBL] [Abstract][Full Text] [Related]
39. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
